NCT04120493: An ongoing trial by UniQure Biopharma B.V.
This trial is ongoing. It must report results 4 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04120493 |
|---|---|
| Title | A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 6, 2019 |
| Completion date | June 30, 2029 |
| Required reporting date | June 30, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |